Remove Generic Drugs Remove Marketing Remove Pharma Companies Remove Production
article thumbnail

Pharma companies in Baddi

Creogenic Pharma

1* Pharma Franchise Company Submit Lowest Price 250+ Products Best Service Best Quality Just a few decades ago Baddi was a town of dust. The land was dull and there were next to zero companies there. We have a vast network of customers throughout the nation who trust us for our quality and affordable products.

article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

Claire D’Abreau-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. What are complex generics?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Nothing epitomises market failures more than the cost of insulin,” Newsom said in a video posted on Twitter. California’s budget documents give few details about the tender process, but state that CalRx will spend $50 million to partner with a contract manufacturer to develop biosimilar insulin products in vial and pen form.

Insulin 328
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. The goal of getting a drug to market as fast as possible so they can recoup drug development costs has the potential for mistakes that could cost lives. Why would a pharma company take risks like these?

article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact.

article thumbnail

In the News: October Regulatory and Development Updates

Camargo

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. In October, the U.S.

article thumbnail

Pharma’s climate change vulnerability and opportunity

pharmaphorum

tons of carbon dioxide equivalent (CO 2 e) for every $1m it generated – placing it above even the automotive industry, which emitted 31.4 tons per $1m generated in the same year, in terms of contributing to global greenhouse gases (GHGs). “As In 2019, the pharmaceutical industry produced 48.55 Vulnerability . Adaptability.